Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday? [Yahoo! Finance]
Cerevel Therapeutics Holdings, Inc. (CERE)
Company Research
Source: Yahoo! Finance
the aggregate, plus one contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million The proposed transaction is expected to close in the second calendar quarter of 2024. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), anti-inflammatory, and facilitates epithelial repair. “With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, first-in-class, oral asset with the potential to make a difference in the lives of people living with ulcerative colitis and Crohn's disease,” said Roopal Thakkar, senior vice president, chief medical officer, global therapeutics, AbbVie. NLRX1 regulates immuno-metabolism and inflammation, and its activation impacts multiple mechanisms of inflammatory bowel disease pathogenesis. The randomized controlled Phase 2 NEXUS clinical trial evaluating
Show less
Read more
Impact Snapshot
Event Time:
CERE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERE alerts
High impacting Cerevel Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERE
News
- Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study [Yahoo! Finance]Yahoo! Finance
- Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s DiseaseGlobeNewswire
- Tavapadon for Parkinson's Disease for 7MM: Market Size, Forecast, and Emerging Insights 2019-2032 - Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan [Yahoo! Finance]Yahoo! Finance
- AbbVie slips after revising guidance to reflect earnings impact [Seeking Alpha]Seeking Alpha
CERE
Earnings
- 11/1/23 - Beat
CERE
Sec Filings
- 4/26/24 - Form 10-K/A
- 4/3/24 - Form 4
- 4/1/24 - Form 144
- CERE's page on the SEC website